The knee jerk is not unusual in heavily shorted BT's of which CYTK is not, so it is a bit odd. I guessed the move to PIII was giving some BB's the tizzies of an offering to pay for the trials, or some people want in at a lower price. The results look ok after only a single dose. IMHO the bottom line is that those that dumped did so on automatic pilot, or have a longer range plan. I nibbled a bit on the way down, there is no harm as far as I can see.
Stocks that warrant a look in the health care sector include Cytokinetics, Inc. CYTK, Acorda Therapeutics, Inc. ACOR and Affymetrix Inc. AFFX. All of these carry a Zacks Rank #1 (Strong Buy). 2013 they said the same thing and CYTK popped to almost double a little later.